InterCure Ltd. Secures Up to $29.8M in Funding
Ticker: INCR · Form: 6-K · Filed: Dec 20, 2024 · CIK: 1857030
| Field | Detail |
|---|---|
| Company | Intercure Ltd. (INCR) |
| Form Type | 6-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: funding, financing, company-update
TL;DR
InterCure just locked down up to $29.8M in new funding!
AI Summary
On December 19, 2024, InterCure Ltd. secured funding commitments totaling NIS 66 million (approximately USD 18.2 million), with the potential to increase to NIS 107 million (approximately USD 29.8 million). This funding involves commitments from specific investors.
Why It Matters
This funding injection provides InterCure Ltd. with capital to support its operations and growth initiatives, potentially impacting its market position and future development.
Risk Assessment
Risk Level: medium — The filing indicates new funding, which is generally positive, but the exact terms and impact on existing shareholders are not fully detailed, warranting a medium risk assessment.
Key Numbers
- USD 29.8M — Maximum Funding (Potential capital infusion for InterCure Ltd.)
- USD 18.2M — Initial Funding (Secured funding amount as of December 19, 2024)
Key Players & Entities
- InterCure Ltd. (company) — Registrant
- NIS 66 million (dollar_amount) — Initial funding commitment
- USD 18.2M (dollar_amount) — Approximate USD equivalent of initial funding
- NIS 107 million (dollar_amount) — Potential maximum funding commitment
- USD 29.8M (dollar_amount) — Approximate USD equivalent of potential maximum funding
- December 19, 2024 (date) — Date of funding commitment
FAQ
What is the total amount of funding InterCure Ltd. has secured?
InterCure Ltd. has secured funding commitments of NIS 66 million (approximately USD 18.2M), with the potential to increase to NIS 107 million (approximately USD 29.8M).
On what date were these funding commitments made?
The funding commitments were secured on December 19, 2024.
Who are the specific investors providing the funding?
The filing mentions 'certain investors' but does not name them specifically in the provided text.
What is the primary business of InterCure Ltd.?
InterCure Ltd. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the principal executive office location for InterCure Ltd.?
The principal executive offices are located at 85 Medinat ha-Yehudim Street, Herzliya, 4676670, Israel.
Filing Stats: 1,116 words · 4 min read · ~4 pages · Grade level 15.6 · Accepted 2024-12-20 08:37:44
Filing Documents
- form6-k.htm (6-K) — 26KB
- ex99-1.htm (EX-99.1) — 22KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-24-050893.txt ( ) — 56KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INTERCURE LTD. Date: December 20, 2024 /s/ Amos Cohen Amos Cohen Chief Financial Officer